ISRCTN98318971已完成不适用
A double-blind, placebo controlled study to assess the effects of early intervention and/or treatment with epoetin alfa on anaemia in cancer patients receiving non-platinum containing chemotherapy
Janssen-Cilag Ltd (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of non-myeloid malignancy, which requires non-platinum containing chemotherapy
- •2. Predicted chemotherapy of 12 to 24 weeks (three to six cycles) duration
- •3. Performance score zero to three
- •4. Life expectancy of more than six months
- •5. Aged over 18 years
- •6. Patients with acute leukaemia are excluded
- •7. No myeloablative chemotherapy
- •8. No uncontrolled hypertension
- •9. No evidence of untreated iron, folate or vitamin B12 deficiency
排除标准
- •Does not comply with the above inclusion criteria
研究者
相似试验
进行中（未招募）
1 期
A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)overactive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-001334-40-GBPLETHORA SOLUTIONS LIMITED112
进行中（未招募）
不适用
A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)overactive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-001334-40-IEPLETHORA SOLUTIONS LIMITED112
已完成
不适用
A double-blind, placebo-controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with symptoms of overactive bladderISRCTN97355181Plethora Solutions Ltd (UK)100
进行中（未招募）
1 期
A study to see how inhaled PC945 affects a fungal infection in patients with asthma or other lung diseases.Pulmonary aspergillosis and candidiasis of lungMedDRA version: 20.0Level: LLTClassification code 10059259Term: Pulmonary aspergillosisSystem Organ Class: 100000004862MedDRA version: 20.0Level: LLTClassification code 10007155Term: Candidiasis of lungSystem Organ Class: 100000004862EUCTR2018-000244-26-GBPulmocide Ltd46
已完成
不适用
A double blind, placebo controlled study to assess the safety and efficacy of PCD-04 as a protective agent against anthracycline-induced cardiotoxicity.CancerBreast cancerISRCTN56637853TT Bio-Pharma (Japan)72